NeuroMOF aims has favoured the opening of a new challenging research line that Dr. Hidalgo is trying to pursue for the next years: new generation of smart nano/micro materials combining MOF features with self-locomotion devices, resulting in attractive penetrating-nanomedicine machines for targeted therapies. Despite other research areas have been benefited with the performance of diverse Janus materials (eg. decontamination, batteries, sensing), the presence of self-propelled MOFs (called as MOFtors) in drug delivery is still at its infancy (<50 articles since 2012, pointing out <10 publications in biomedicine in 2022-23). Thus, there is still room for the investigations of MOF self-locomotion and their potential biopermeability. Taking in account the increasing MOF trend in academic and industrial domains together with the potential of these micro/nanomotor technology, the prestigious support received by the MSCA Individual Fellow, it has encouraged and enhanced the candidate expertise providing an excellent research & valuable finding on this hot topic such as the nanoMOF neuronal delivery trough the BBB crossing. Considering the scientific background of Dr. Hidalgo (MOF platforms, drug delivery, biology or immunology) and her contribution during the last years in the MOF biological field, it´s important to highlight that further progress in this challenging topic will boost her profile to young leader research positions, not only at the junior level but also to more independent senior status. In addition, the raised trans-disciplinary MOFtor approach will significantly contribute to develop breakthrough enabling-technologies (mainly at biomedical science & chemical engineering fields) since, the wealth of fundamental knowledge potentially generated here (eg. MOFtor stability, muco-diffusion, cellular or immune-repercussion, etc.) will be highly valuable for other socioeconomic relevant fields such as challenging illnesses (eg. infectious, neurological, cardiovascular), environment, catalysis or sensing, among others. In fact, this hot topic is highly accordance with the 5 missions marked by the EU in Horizon2020 (eg. design of advanced materials to meet specific applications needs such as cancer, climate-change adaptation, oceans restoration, etc.), thus, if this MOFtor technology investigation continue in a fruitful and result-oriented manner, not only the patient ‘quality-life would be significantly transformed, but also will potentially reduce the current healthcare costs (€380bn for EU countries). Therefore, NeuroMOF project has served as starting point for shedding light on potential triggered mobility mechanisms for a safe tissue penetration and more targeted & effective MOF therapies, which could impact on the EU healthcare system in a medium-long term.